公司背景 - [1] 第42届摩根大通医疗健康年会是全球生物医药健康领域规模最大的行业盛会 - [3] 雅培公司的野心是到2030年帮助改善30亿人的生活，并且是仅有的49家始终存在于《财富》500强榜单中的公司之一 - [4] 雅培在全球的员工超过115,000名，服务于160多个国家，公司以一系列知名的品牌建立了良好形象，这些品牌年销售额超过400亿美元，在过去10年翻了一番 - [5] 雅培有一半以上的收入来自美国以外的地区，有三分之一的收入来自新兴市场，公司核心业务、基础业务再次成为其业绩推动力，包括2023年前三季度实现两位数的有机销售增长 业务领域 - [6] 雅培的业务分为医疗器械、营养、诊断和药品四个部分，其中在医疗器械方面，雅培在心血管、神经调控和糖尿病护理方面处于市场领先地位 - [7] 雅培在心脏管理、心力衰竭、电生理学、结构性心脏、冠状动脉和外周血管等领域占据领导地位 - [8] 雅培的TriClip是世界上第一款用于治疗三尖瓣反流或三尖瓣渗漏的微创夹式修复设备，目前正在接受FDA的审查，以获得美国的批准 - [10] 雅培的Aveir是一款无导线起搏器，与传统起搏器不同之处在于不需要在胸部切口，这是世界上第一个提供双腔起搏的无导线起搏系统 市场发展和战略 - [15] 雅培的战略是瞄准大众市场，Libre的出现满足了市场对无痛、高度准确、易于使用且具有成本效益的系统的需求，目前Libre的年销售额不会超过50亿美元 - [17] 可穿戴设备Lingo有望成为雅培下一个巨大的成长催化剂，可以追踪血糖水平，同时还能借助应用程序为使用者提供个性化的饮食和锻炼建议，这款设备很快就会进入美国市场 技术创新 - [19] 雅培公司确定了人工智能在医疗保健中的三个重要领域 - [19] Ultreon血管成像软件利用人工智能自动检测血管中的钙水平，帮助医生做出更准确的治疗决策 发展前景 - [21] 雅培公司去年进行了两次收购以扩大投资组合，目前管线健康，完全可以保持高个位数的有机增长

Abbott (ABT) closed at $113.92 in the latest trading session, marking a +0.37% move from the prior day. This change outpaced the S&P 500's 0.08% gain on the day. Meanwhile, the Dow lost 0.31%, and the Nasdaq, a tech-heavy index, added 0.02%.Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 4.51% over the past month, lagging the Medical sector's gain of 6.57% and outpacing the S&P 500's gain of 3.52% in that time.Market participants will be closely following the ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this maker of infant formula, medical devices and drugs have returned +4.5% over the past month versus the Zacks S&P 500 composite's +3.5% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 5.8% over this period. Now the key question is: Where could the stock be headed in the near ter ...

Abbott (ABT) ended the recent trading session at $112.73, demonstrating a +0.29% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.15%. At the same time, the Dow lost 0.42%, and the tech-heavy Nasdaq gained 0.09%.The maker of infant formula, medical devices and drugs's stock has climbed by 5.82% in the past month, falling short of the Medical sector's gain of 6.58% and outpacing the S&P 500's gain of 3.5%.Investors will be eagerly watching for the performance of ...

公司概况 - Abbott是一家全球高科技医疗领导者，在全球160个国家拥有超过115,000名员工，年销售额超过400亿美元，业务涵盖医疗器械、营养品、诊断和药品四大领域[3] - Abbott的核心业务包括医疗器械、营养品、诊断和药品，其中在医疗器械领域拥有心血管、神经调节和糖尿病护理等领先地位[6] - Abbott的市场领先产品FreeStyle Libre是一款市场领先的可穿戴葡萄糖传感器，已经在全球拥有超过500万用户，销售额超过50亿美元，并在不断拓展新的增长机会[13] 资本配置策略 - Abbott的资本配置策略包括持续增长的股息、内部资本投资、股票回购和并购机会，通过健康的资产负债表实现多元化资本配置目标[22] - 公司在资本配置方面的核心原则是持续增长的股息，并且会谨慎评估M&A机会，确保为股东带来短期和长期的回报[48] 产品创新和发展 - 公司在未来几年内将继续关注产品创新和推出新产品，如TriClip和Aveir等，以推动业务的增长和利润提升[57] - 公司在医疗器械、制药和营养产品领域利用人工智能技术，帮助医生提供更准确的诊断和治疗方案，提高产品性能和用户体验[25] 毛利率和定价策略 - 公司在过去几年中成功应对环境挑战，尤其是在毛利率方面存在一些挑战，但团队已经开始着手解决这个问题[42] - 公司专注于提高毛利率，通过降低成本、优化库存管理和利用产品组合优势等方式来实现毛利率的提升[43] - 公司在定价方面一直以增加销量为主要目标，但在某些业务领域，定价已经成为增长率的一个因素，尤其是在医疗设备领域[61] 未来展望 - 公司预计在2024年将继续保持增长势头，业务增长速度将超过疫情前的水平，展望未来的发展前景乐观[69]

分红对投资者的重要性 - 分红可以提供 passsive income，帮助减少其他头寸的回撤影响，并通过再投资分红实现最大回报[1] - 公司能够持续支付和增加分红表明其财务状况稳定健康，分红提升有助于传递积极信息，增强投资者对公司长期前景的信心[2] 三家公司的分红增长 - Enterprise Product Partners (EPD)、Abbott Laboratories (ABT)和Broadcom (AVGO)都在不断增加他们的分红[3]

Abbott Laboratories (ABT) is well-poised for growth in the coming quarters, driven by solid prospects in the core Diagnostics business. The raised 2023 outlook buoys optimism. However, forex woes and lower COVID sales impede growth.In the past six months, this Zacks Rank #3 (Hold) stock has gained 4.6% compared with 4.8% decline of the industry and a 7.8% rise of the S&P 500 composite.This renowned provider of a diversified line of healthcare products has a market capitalization of $192.36 billion. The comp ...

With smartwatches, fitness trackers, smart clothing and smart glasses, the wearable market has grown exponentially in the last few years. Per a Statista report, nearly 150 million wearables were shipped worldwide in Q3 2023 alone. However, beyond simply tracking steps or serving as smart health devices, wearables have far evolved to become one of the most attractive investment opportunities in today's market.For investors who are keen on tapping the rising prospects of prospering wearable technology within ...

John Kevin/iStock via Getty Images Let me wish you a Happy New Year once more! We have a hot list of seven stocks increasing their dividends next week on tap. This week is bolstered by Dividend King Hormel (HRL), Mastercard (MA) and the "Abbott's," Abbott Laboratories (ABT), and AbbVie (ABBV), the drug company spinoff from Abbott in 2012. For the sake of the discussion, the streaks refer to each company's growing annual dividend. I know that Abbott's history goes back over 50 years, but the rules for inclus ...

Abbott Laboratories的业务表现 - Abbott Laboratories是医疗行业的长期领导者，尽管近年来遇到了一些挑战，但公司仍然有望从最近的困境中反弹，继续提供出色的回报[1] - Abbott Laboratories在过去几年中的营收、利润和自由现金流都呈现增长趋势，这是一个积极的迹象[4] Abbott Laboratories的市场前景 - 长期趋势将是关键，由于人口老龄化和医疗需求增加，这将为Abbott的业务提供重要的推动力[3] - Abbott的FreeStyle Libre连续葡萄糖监测产品在糖尿病护理市场上取得了领先地位，为公司带来了巨大增长[6] Abbott Laboratories的股息政策 - Abbott的股息政策非常优秀，连续51年提高股息，对于长期投资者来说非常重要[11]